Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models
C.M. Carruthers, S. Barat, D. Angulo, P. Thomas, E. Lewis, R. SobelACOG 2019
May 2019
ACOG 2019
May 2019
A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp in Vulvovaginal Candidiasis (DOVE)
P. Nyirjesy, R. Cadet, M. Tufa, D. AnguloACOG 2019
May 2019
Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)
Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019
Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study
D Juneja, O Singh, B Tarai, DA AnguloECCMID 2019
April 2019
Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study
Philipp Koehler, Oliver A. Cornerly, David AnguloECCMID 2019
April 2019
Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study
J Vazquez, Aprile Osborn, D AnguloECCMID 2019
April 2019
Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model
Annie Lee, Brendan Prideaux, Min Hee Lee, Matthew Zimmerman, Padmaja Paderu, Stephen A. Barat, David Angulo, David S. Perlin, Yanan ZhaoECCMID 2019
April 2019
Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model.
Stephen A. Barat, Katyna Borroto-Esoda, David A. Angulo, Alan Ashbaugh, Melanie CushionECCMID 2019
April 2019
